Table 2.
Characteristics of screening serum sets
| |
1st sampling test |
Validation test |
|---|---|---|
| Sampling periods | 1998-2005 | 2005-2008 |
|
No. of patients |
128 |
115 |
| Healthy donors, n (%) |
56 (43.8) |
48 (41.7) |
| Age (mean ± SD), range |
48.1 ± 18.3, 16-76 |
51.3 ± 15.2, 16-76 |
| Low-grade glioma, n(%) |
40 (31.3) |
42 (36.5) |
| Age (mean ± SD), range |
45.8 ± 14.8, 20-74 |
44.2 ± 14.1, 22-78 |
| Pilocytic astrocytoma, n (%) |
2 (5.0) |
4 (9.5) |
| Diffuse astrocytoma, n (%) |
18 (45.0) |
15 (35.7) |
| Oligodendroglioma, n (%) |
16 (40.0) |
19 (45.2) |
| Oligoastrocytoma, n (%) |
3 (7.5) |
1 (2.4) |
| Ependymoma, n (%) |
1 (2.5) |
|
| Ganglioglioma, n (%) |
|
3 (7.1) |
| High-grade glioma, n (%) |
32 (25.0) |
25 (21.7) |
| Age (mean ± SD), range |
49.7 ± 18.3, 8-78 |
49.8 ± 15.5, 28-78 |
| Glioblastoma, n (%) |
24 (75.0) |
17 (68.0) |
| Anaplastic astrocytoma, n (%) |
5 (15.6) |
3 (12.0) |
| Anaplastic oligodendroglioma, n (%) |
2 (6.3) |
2 (8.0) |
| Anaplastic oligoastrocytoma, n (%) |
1 (3.1) |
1 (4.0) |
| Anaplastic ependymoma, n (%) |
|
1 (4.0) |
| Choroid plexus carcinoma, n (%) | 1 (4.0) |